A clinical study designed to develop and inform an individual risk of hemolysis model based
on individual red blood cell G6PD levels. Volunteers who are eligible to treatment with
primaquine as per national guidelines and with confirmed normal G6PD levels as per the
fluorescent spot test will be exposed to treatment regimens of either primaquine alone for 14
days or 3 day chloroquine with concomitant primaquine for 14 days. The volunteers will be
followed intensively during treatment and for 14 days after treatment for haematologic
measures, G6PD quantification, and drug level assays.